How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?

被引：1
|
作者：
De La Rosa, Carlos Aguado
Carbonero, Iciar Garcia
De Velasco, Guillermo
Alonso, Teresa
Villalobos, Maria L.
Garrido, Maria
Gallegos, Isabel
Martin, Almudena
Pinto, Alvaro
Alonso, Constanza Maximiano
Rodriguez-Moreno, J. F.
Rodriguez, Laura
Sereno, Maria
Perezagua, Carmen
Marrupe, David
Riquelme, Alejandro
Cassinello, Javier
Grande, Enrique
Puente, Javier
Gajate, Pablo
机构：
[1] Hosp Univ Clin San Carlos, Madrid, Spain
[2] Hosp Virgen Salud, Toledo, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Univ Ramon y Cajal, Madrid, Spain
[5] Hosp Univ Principe Asturias, Madrid, Spain
[6] Hosp Univ Severo Ochoa, Madrid, Spain
[7] Hosp Gen Segovia, Segovia, Spain
[8] Hosp Infanta Leonor, Madrid, Spain
[9] Hosp Univ La Paz, Madrid, Spain
[10] Hosp Univ Puerta Hierro, Madrid, Spain
[11] Ctr Integral Oncol Clara Campal, Madrid, Spain
[12] Hosp Univ Fuenlabrada, Fuenlabrada, Spain
[13] Hosp Univ Infanta Sofia, Madrid, Spain
[14] Hosp Univ Henares, Coslada, Spain
[15] Hosp Univ Mostoles, Mostoles, Spain
[16] Hosp Univ Infanta Cristina, Parla, Spain
[17] Hosp Univ Guadalajara, Guadalajara, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e16504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16504
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer
    Tsao, Phoebe A.
    Caram, Megan E. V.
    CANCER JOURNAL, 2020, 26 (01): : 76 - 82
  • [22] Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
    Sigurdson, Samantha S.
    Vera-Badillo, Francisco E.
    de Moraes, Fabio Ynoe
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection
    Gafanov, R. A.
    Dzidzaria, A. G.
    Kravtsov, I. B.
    Fastovets, S. V.
    ONKOUROLOGIYA, 2018, 14 (04): : 139 - 149
  • [24] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [25] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
  • [26] Patients with metastatic prostate cancer. Recommendations for primary hormonal or chemohormonal therapy
    Ohlmann, C. -H.
    UROLOGE, 2017, 56 (11): : 1424 - 1429
  • [27] Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer
    Borque-Fernando, A.
    Perez-Fentes, D. A.
    Rodrigo-Aliaga, M.
    Puente-Vazquez, J.
    Gomez-Iturriaga, A.
    Unda, M.
    Calleja-Hernandez, M. A.
    Cozar-Olmo, J. M.
    alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (10): : 703 - 717
  • [28] Selecting Patients With Metastatic Hormone- Sensitive Prostate Cancer for Combination Therapy
    Lam, Anthony P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (09)
  • [29] Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer Reply
    McManus, Hannah D.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3874 - +
  • [30] Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer
    Naito, Yushi
    Kato, Masashi
    Kawanishi, Hideji
    Yamamoto, Akiyuki
    Sakamoto, Fumitoshi
    Hirabayashi, Hiroki
    Kobayashi, Masataka
    Matsukawa, Yoshihisa
    Kimura, Tohru
    Araki, Hidemori
    Nishikimi, Toshinori
    Kondo, Atsuya
    Yoshino, Yasushi
    Hashimoto, Yoshimasa
    Nakano, Yojiro
    Tsuzuki, Toyonori
    PROSTATE, 2023, 83 (04): : 307 - 315
12345